Cargando…

Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria

For patients with advanced hepatocellular carcinoma (HCC), sorafenib is the only systemic treatment recommended by international guidelines. We recently reported that HCC patients with a low MoRAL (model to predict tumor recurrence after LDLT) score (≤ 314.8) have excellent treatment outcomes after...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Yuri, Lee, Jeong-Hoon, Lee, Dong Hyeon, Cho, Eun Ju, Yu, Su Jong, Yi, Nam-Joon, Lee, Kwang-Woong, Kim, Yoon Jun, Yoon, Jung-Hwan, Suh, Kyung-Suk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564586/ https://www.ncbi.nlm.nih.gov/pubmed/28548930 http://dx.doi.org/10.18632/oncotarget.17733

Ejemplares similares

Sirolimus Prolongs Survival after Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond Milan Criteria: A Prospective, Randomised, Open-Label, Multicentre Phase 2 Trial
por: Lee, Kwang-Woong, et al.
Publicado: (2020)

Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence
por: Kang, Seong Hee, et al.
Publicado: (2018)

Living donor liver transplantation should be cautiously considered as initial treatment in recurrent hepatocellular carcinoma within the Milan criteria after curative liver resection
por: Kim, Jong Man, et al.
Publicado: (2020)

Liver transplantation for hepatocellular carcinoma beyond the Milan criteria
por: Xu, Xiao, et al.
Publicado: (2016)

Living donor liver transplantation for hepatocellular carcinoma beyond the Milan criteria: outcome of expanded criteria in tumor size
por: Liang, Hsin-Rou, et al.
Publicado: (2021)

Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study
por: Teng, Chieh-Lin, et al.
Publicado: (2012)

Living Donor Liver Transplantation: The Optimal Curative Treatment for Hepatocellular Carcinoma Even Beyond Milan Criteria
por: Alim, Altan, et al.
Publicado: (2021)

Liver Transplantation Beyond Milan Criteria
por: Lingiah, Vivek A, et al.
Publicado: (2020)

Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome
por: Kornberg, A.
Publicado: (2014)

Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review
por: Toniutto, Pierluigi, et al.
Publicado: (2021)

Sarcopenia as a predictor of post-transplant tumor recurrence after living donor liver transplantation for hepatocellular carcinoma beyond the Milan criteria
por: Kim, Young Ri, et al.
Publicado: (2018)

Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis
por: Zhou, Qunfang, et al.
Publicado: (2022)

Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study
por: Kim, Hwi Young, et al.
Publicado: (2018)

Chemoembolization combined radiofrequency ablation vs. chemoembolization alone for treatment of beyond the Milan criteria viable hepatocellular carcinoma (CERFA): study protocol for a randomized controlled trial
por: Lee, Soon Kyu, et al.
Publicado: (2023)

Impact of muscle mass on survival of patients with hepatocellular carcinoma after liver transplantation beyond the Milan criteria
por: Beumer, Berend R., et al.
Publicado: (2022)

International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria
por: Degroote, Helena, et al.
Publicado: (2021)

Influence of Body Mass Index ≥30 on Pure Laparoscopic Donor Right Hepatectomy
por: Hong, Suk Kyun, et al.
Publicado: (2020)

Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis
por: Zhou, Qunfang, et al.
Publicado: (2022)

Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK
por: Lee, Seulki, et al.
Publicado: (2018)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
por: Lee, Cheol-Hyung, et al.
Publicado: (2020)

Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib
por: Yoo, Jeong-Ju, et al.
Publicado: (2018)

Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma
por: Yoo, Jeong-Ju, et al.
Publicado: (2019)

Wearable recording video technology for surgical training in living donor liver transplantation
por: Lee, Shin Ae, et al.
Publicado: (2020)

Outcomes of Living Donor Liver Transplantation in Patients With a History of Ruptured Hepatocellular Carcinoma
por: Lee, Hwi Yeol, et al.
Publicado: (2021)

Pure 3D laparoscopy versus open right hemihepatectomy in a donor with type II and III portal vein variations
por: Park, Kyungho, et al.
Publicado: (2019)

CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma
por: Chang, Young, et al.
Publicado: (2020)

No diffuse intrahepatic biliary stricture after ABO-incompatible adult living donor liver transplantation using tailored rituximab-based desensitization protocol
por: Natsuda, Koji, et al.
Publicado: (2021)

Assessment of the Surveillance Interval at 1 Year after Curative Treatment in Hepatocellular Carcinoma: Risk Stratification
por: Lee, Minjong, et al.
Publicado: (2018)

Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria
por: Zhang, Lan, et al.
Publicado: (2014)

Transarterial chemoembolization with radiofrequency ablation versus hepatectomy in hepatocellular carcinoma beyond the Milan criteria: a retrospective study
por: Yuan, Hang, et al.
Publicado: (2018)

Efficacy and safety of lenvatinib for preventing tumor recurrence after liver transplantation in hepatocellular carcinoma beyond the Milan criteria
por: Guo, De-Zhen, et al.
Publicado: (2022)

Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions
por: Pavel, Mihai-Calin, et al.
Publicado: (2018)

Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study
por: Chang, Young, et al.
Publicado: (2019)

Optimal Tailored Screening Protocol after Living Donor Liver Transplantation for Hepatocellular Carcinoma
por: Park, Min-Su, et al.
Publicado: (2014)

Recurrence Beyond the Milan Criteria of HBV-Related Single Hepatocellular Carcinoma of 2–3 cm: Comparison of Resection and Ablation
por: Chen, Shuanggang, et al.
Publicado: (2021)

Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy
por: Shen, Junyi, et al.
Publicado: (2022)

Patients Benefit from Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria without Harming the Health Care System
por: Gundlach, Jan-Paul, et al.
Publicado: (2022)

Optimal Intervention for Initial Treatment of Anastomotic Biliary Complications After Right Lobe Living Donor Liver Transplantation
por: Kim, Min Seob, et al.
Publicado: (2022)

A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
por: Lee, Jeong-Hoon, et al.
Publicado: (2015)

Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
por: Lee, Sangheun, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ls725ckhf0177r3jhup46a2sab